It will take all of us, working together, to urgently propel research to make ALS a livable disease until new treatments and a cure are ultimately found.
This month, learn more about the latest news and updates on tofersen, new ALS research funding opportunities and ongoing ALS clinical trials.
FDA announced it will seek advice on whether tofersen should be approved to treat a specific form of ALS on the strength of biomarker data during an upcoming advisory committee meeting scheduled for March 22.
Biospecimens from NurOwn's placebo-controlled Phase 3 ALS trial will be donated to the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) biorepository for use by the research community thanks in part to a grant previously awarded to BrainStorm by The ALS Association and I AM ALS.
The gene editing system was used to remove the repeat expansion in the C9ORF72 gene (the most common genetic cause ALS) in mouse models and human cells, providing positive proof-of-concept results.
The ALS Association has awarded more than $700,000 to support five promising early career scientists through its Milton Safenowitz Postdoctoral Fellowship Program.
A wide range of equipment and technologies can help improve mobility and manage symptoms as ALS progresses, making it easier for people living with the disease to get around their homes, speak and perform day-to-day tasks. Supporting scientific advancements in assistive technology is just one focus area enabling us to help improve the lives of people living with ALS.
ALS Focus allows people living with ALS, and current and former caregivers the ability to participate in research outside of clinical trials and is available to all at any stage of the disease. Your opinions help strengthen care, accelerate therapy development, improve clinical trials, influence insurance coverage decisions, and more.
Register to participate in future surveys HERE, and let your voice be heard.
Clinical research is the only way that promising laboratory science can be translated into treatments and cures for ALS and other neurological diseases. People with ALS, along with family members and caregivers, are essential partners in this research. For the most accurate and up-to-date information on both federally and privately funded clinical studies focusing on ALS and other similar motor neuron diseases, visit our website.
The National ALS Registry may be the single largest ALS research project ever created and is designed to identify ALS cases from throughout the entire United States. Every person living with ALS in the U.S. can take part, and there is no fee to participate.
The ALS Association partners with the Northeast ALS Consortium (NEALS) to provide educational webinars for people with ALS, caregivers, and the broader ALS community. Topics include updates on clinical trials, best practices for clinical care, and current research efforts in ALS causes and treatments.
For more detail about current ALS research, the projects we fund, and the numerous focus areas we support, visit als.org/research.
Stay up to date with the latest ALS care news by signing up for our quarterly e-newsletter, Care Matters.
We welcome all feedback, comments and questions you may have on anything about the information provided, suggestions of topics you would like to see in future newsletters or thoughts to help us improve. Please email us at communication@alsa-national.org.